Literature DB >> 3974052

Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization.

C E Stevens, P T Toy, M J Tong, P E Taylor, G N Vyas, P V Nair, M Gudavalli, S Krugman.   

Abstract

Among infants born to women in whom sera are positive for both the hepatitis B surface antigen and the e antigen, 85% to 90% are infected with hepatitis B virus and become chronic hepatitis B surface antigen carriers. In a study to assess the effectiveness of passive-active prophylaxis (hepatitis B immune globulin and hepatitis B vaccine) of such infants, we screened 18,842 pregnant Asian-American women: 8.7% were positive for hepatitis B surface antigen and 3.0% were also positive for hepatitis B e antigen. Thus far, 113 infants have received hepatitis B immune globulin (0.5 mL at birth) and hepatitis B vaccine (three 20-micrograms doses beginning at birth or at 1 month) and have been followed up for nine to 18 months. Among these infants, 16 have become chronic carriers, an incidence of only 14.2%. All of the uninfected infants have retained high levels of antibody to surface antigen, suggesting that they have had an active immune response to the vaccine and should have long-term protection against hepatitis B virus.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3974052

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  59 in total

1.  Missed opportunities for prevention of perinatal transmission of hepatitis B: a retrospective cohort study.

Authors:  Julie van Schalkwyk; Melica Nourmoussavi; Andrea Massey; Reka Gustafson; Elizabeth Brodkin; Martin Petric; Mel Krajden; Simon Dobson; Jane Buxton; Mark Bigham; Neora Pick; Rick Schreiber; Christopher H Sherlock; Deborah Money; Eric M Yoshida
Journal:  Can J Gastroenterol Hepatol       Date:  2014-11

2.  Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.

Authors:  Hui-Fang Hung; Hsiu-Hsi Chen
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

3.  Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.

Authors:  G M Ginsberg; D Shouval
Journal:  J Epidemiol Community Health       Date:  1992-12       Impact factor: 3.710

Review 4.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

5.  Predictors of hepatitis B immunization status in Korean American children.

Authors:  Y O Kim; S Telleen
Journal:  J Immigr Health       Date:  2001-10

6.  Screening for hepatitis B during pregnancy. Awareness of current recommendations among Washington hospitals.

Authors:  T R Eng; M L Borges; V K Harlin; J M Kobayashi
Journal:  West J Med       Date:  1991-12

Review 7.  Management of chronic hepatitis B in patients from special populations.

Authors:  Ching-Lung Lai; Man-Fung Yuen
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

Review 8.  Hepatitis B During Pregnancy in Endemic Areas: Screening, Treatment, and Prevention of Mother-to-Child Transmission.

Authors:  Naichaya Chamroonkul; Teerha Piratvisuth
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

9.  Perinatal hepatitis B prevention program in Shandong Province, China. Evaluation and progress.

Authors:  Li Zhang; Stephen Ko; Jingjing Lv; Feng Ji; Bingyu Yan; Fujie Xu; Aiqiang Xu
Journal:  Hum Vaccin Immunother       Date:  2014-11-06       Impact factor: 3.452

Review 10.  Hepatitis B in pregnancy.

Authors:  J A Arevalo
Journal:  West J Med       Date:  1989-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.